Obesity

Top Story

Bone loss remains elevated 5 years after RYGB vs. sleeve gastrectomy

Bone loss remains elevated 5 years after RYGB vs. sleeve gastrectomy
November 21, 2017

Adults with uncontrolled type 2 diabetes and obesity treated with Roux-en-Y gastric bypass surgery vs. sleeve gastrectomy or intensive medical therapy had elevated bone turnover markers 5 years later, study data show.

Sangeeta Kashyap, MD, of the department of endocrinology, diabetes and metabolism at Cleveland Clinic, and colleagues evaluated data from the STAMPEDE trial on 95 adults (mean age, 48.5 years) with uncontrolled type 2 diabetes and obesity (mean BMI, 36.5 kg/m2) randomly assigned to intensive medical therapy (n = 25), Roux-en-Y gastric bypass (RYGB; n = 37) or sleeve gastrectomy (n = 33) to determine the 5-year outcomes on bone turnover.

In the Journals Plus

Age at menarche associated with hypertension, obesity risk

November 20, 2017
Chinese women who experience late menarche are more likely to develop hypertension in adulthood but less likely to develop obesity vs. women who reach menarche at age 14…
Meeting News

High BMI linked to larger breast cancer tumor size

November 20, 2017
BMI was the only consistent risk factor for detecting breast tumors larger than 2 cm among women, according to findings being presented at next week’s annual…
In the Journals

AAP: Empathetic counseling needed to address pediatric obesity stigma

November 20, 2017
A ‘patient first’ approach using positive language and actions is encouraged when treating children who have overweight or obesity to reduce the stigma…
More Headlines »
CME

Best of Obesity Forum® 2017

This activity is supported by an educational grant from Novo Nordisk, Inc.

The incidence of obesity has increased dramatically over the past 20 years and is considered to be an epidemic in the…
More »
Video
Meeting News

VIDEO: Patients not seeking, providers not offering enough obesity care

November 2, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

CME

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic…
More »
Advertisement
Advertisement